13F-HR filed by Sarissa Capital Management LP
Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2017-06-30, filed 2017-08-14, with 8 holding rows worth $299,557,000.
- Accession
- 0001140361-17-032001
- Filer
- CIK 1577524
- Filed
- 2017-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2017
A holdings report, 8 entries on the cover page, a total value of $299,557,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $299,557,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| BIOGEN INC COM | 09062X103 | Stock | 383,858 | $104,163,000 | thousands by filing date | |
| BIOVERATIV INC | 09075r100 | COM | 1,165,000 | $70,098,000 | thousands by filing date | |
| MEDICINES CO | 584688105 | COM | 1,752,000 | $66,593,000 | thousands by filing date | |
| INNOVIVA INC | 45781M101 | COM | 3,490,705 | $44,681,000 | thousands by filing date | |
| NOVELION THERAPEUTICS INC | 67001K202 | COM NEW | 1,025,000 | $9,460,000 | thousands by filing date | |
| ADVAXIS INC | 007624208 | COM NEW | 339,180 | $2,201,000 | thousands by filing date | |
| APRICUS BIOSCIENCES INC | 03832V307 | COM NEW | 1,447,906 | $1,636,000 | thousands by filing date | |
| AbbVie,Inc. | 00287Y109 | COM | 10,000 | $725,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001140361-17-032001 | this filing | 2017-08-14 | acceptance time not in the bulk data set |